Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Preclinical Development

Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol

Jenna L. Riffell, Reiner U. Jänicke and Michel Roberge
Jenna L. Riffell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reiner U. Jänicke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Roberge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-10-0909 Published May 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Mitotic slippage occurs through proteasome-dependent degradation of mitotic checkpoint proteins. A, T98G cells arrested in mitosis by 30 nmol/L paclitaxel were harvested by shake-off, seeded in 96-well plates, and exposed to 5 μmol/L SU6656 or 5 μmol/L geraldol simultaneously with 0 to 75 μmol/L MG-132. After 4 hours, the attached, slipped cells were fixed, stained, and quantified using an automated fluorescence imager. Error bars represent 95% CIs. B, mitotic T98G cells were harvested by shake-off and exposed to 5 μmol/L SU6656 or 5 μmol/L geraldol without or with 20 μmol/L MG-132 for 4 hours. Lysates were immunoblotted for the indicated proteins. C, cycling T98G cells were exposed to 5 μmol/L SU6656 or 5 μmol/L geraldol for 4 hours without or with 20 μmol/L MG-132, lysed, and immunoblotted for the indicated proteins.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Mitotic checkpoint inactivation but not cyclin B1 degradation occurs through caspase-3–dependent cleavage of BubR1. A, T98G cells were arrested in mitosis by 30 nmol/L paclitaxel, harvested by shake-off, and seeded in 96-well plates. After exposure to 5 μmol/L SU6656 or 5 μmol/L geraldol simultaneously with 0 to 100 μmol/L Ac-DEVD-CHO for 4 hours, the slipped cells were stained with Hoechst 33342 and quantified by automated fluorescence microscopy. Error bars represent 95% CIs. B, mitotic T98G cells were harvested by shake-off and incubated with 5 μmol/L SU6656 or 5 μmol/L geraldol without or with 50 μmol/L DEVD-CHO for 4 hours. Lysates were immunoblotted for the indicated proteins. C, MCF-7 cells stably transfected with empty vector (MCF-7pcDNA) or caspase-3 (MCF-7casp3) were arrested in mitosis by 50 nmol/L paclitaxel, harvested by shake-off, and seeded in 96-well plates. The cells were exposed to 0 to 15 μmol/L SU6656 or geraldol for 4 hours, stained with Hoechst 33342, and quantified using an automated fluorescence imager. Error bars represent 95% CIs. D, mitotic MCF-7pcDNA and MCF-7casp3 cells were harvested by shake-off and incubated with 5 μmol/L SU6656 or 5 μmol/L geraldol without or with 20 μmol/L MG-132 for 4 hours. Lysates were immunoblotted for the indicated proteins. E, MCF-7pcDNA or MCF-7casp3 cells were exposed to 100 nmol/L paclitaxel for up to 28 hours, and nuclei were fixed and stained with Hoechst 33342. The total number of cells was quantified using automated fluorescence microscopy, and the images were visually inspected to determine the proportion of slipped and mitotic cells at each time.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Timeline of mitotic checkpoint inactivation and slippage. A, T98G cells arrested in mitosis by 30 nmol/L paclitaxel were harvested by shake-off, seeded in 96-well plates, and incubated with DMSO or 5 μmol/L geraldol for 15 minutes to 3 hours. Slipped cells were quantified after staining with Hoechst (left) or with mouse TG3 antibody against mitotically phosphorylated nucleolin (right). The proportion of slipped cells was lower than usually observed because of the numerous washes during immunofluorescent staining that removed many attached, slipped cells. Error bars represent 95% CIs. B, cycling T98G cells (U) were arrested in mitosis by exposure to 30 nmol/L paclitaxel and harvested by shake-off. Mitotic cells (M) were incubated with 5 μmol/L SU6656 or 5 μmol/L geraldol for 15 minutes to 3 hours and lysates were immunoblotted for the indicated proteins.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Inhibition of Aurora A and Aurora B by SU6656 and geraldol. A, SU6656 and geraldol were assayed for in vitro inhibition of Aurora A and Aurora B as described in Materials and Methods. B, MCF-7 cells were arrested in mitosis by 50 nmol/L paclitaxel for 20 hours, harvested by shake-off, seeded in 96-well plates, and incubated with 0.1 to 20 μmol/L ZM447439 for 4 hours. Cells were fixed, stained with Hoechst 33342, and imaged by automated fluorescence microscopy. Error bars represent 95% CIs.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Dependence of the outcome of spontaneous and induced mitotic slippage on caspase-3. A, slipped cells, MCF-7pcDNA and MCF-7casp3 cells were exposed to 50 nmol/L paclitaxel for 20 hours, harvested by shake-off, and seeded in 96-well plates. After exposure to 0.1% DMSO, 5 μmol/L SU6656, or 5 μmol/L geraldol for 4 hours, unattached (mitotic) cells were removed and adherent (slipped) cells were allowed to grow in fresh culture medium for up to 14 days before staining with Hoechst and quantification as a proportion of mitotic cells by automated fluorescence microscopy. B and C, all cells and viable cells, MCF-7pcDNA or MCF-7casp3 cells in 96-well plates were exposed to 0.1% DMSO or 50 nmol/L paclitaxel for 20 hours and then 0.1% DMSO, 5 μmol/L SU6656, or 5 μmol/L geraldol for a further 4 hours. Drugs were washed away and the cells were allowed to grow in fresh culture medium for up to 14 day before staining with Hoechst and quantification (all cells) or analysis of cell viability by the MTT assay (viable cells). Error bars represent 95% CIs.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Model for spontaneous and induced mitotic slippage.

Additional Files

  • Figures
  • Supplementary Data, Riffell, et al.

    Files in this Data Supplement:

    • Supplementary Figure 1
    • Supplementary Figure 2
    • Supplementary Figure 3
    • Supplementary Table 1
    • Supplementary Figure and Table Legends
PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (5)
May 2011
Volume 10, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol
Jenna L. Riffell, Reiner U. Jänicke and Michel Roberge
Mol Cancer Ther May 1 2011 (10) (5) 839-849; DOI: 10.1158/1535-7163.MCT-10-0909

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol
Jenna L. Riffell, Reiner U. Jänicke and Michel Roberge
Mol Cancer Ther May 1 2011 (10) (5) 839-849; DOI: 10.1158/1535-7163.MCT-10-0909
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflict of Interest
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PSMA-Specific BiTE Antibody
  • BiKEs and TriKEs Enhance NK Cell Effector Function
  • Ganetespib Activity in KRAS-Mutant NSCLCs
Show more Preclinical Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement